Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Eltanexor · KPT-8602

Small molecule · Inhibitor of exportin-1 (XPO1/CRM1) (XPO1) · developed by Karyopharm Therapeutics

Phase 1/2 Most advanced trial
KPTI Developer
2 Registered trials

What is Eltanexor?

Eltanexor (KPT-8602) is an orally bioavailable selective inhibitor of nuclear export that binds the cargo-binding site of exportin-1 (XPO1). By blocking XPO1-mediated export, it retains tumor suppressor proteins such as p53 in the nucleus of tumor cells, promoting apoptosis. It is studied in myelodysplastic syndrome, acute myeloid leukemia, multiple myeloma and colorectal and prostate cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
KPT-8602
Drug type
Small molecule
Targets
exportin-1 (XPO1/CRM1) (XPO1)
Mechanism
Inhibitor of exportin-1 (XPO1/CRM1) (XPO1)
Pathways
nuclear export of tumor suppressor proteins, apoptosis
Therapy area
Oncology
Developer
Karyopharm Therapeutics Inc (KPTI)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
Q59IQJ9NTK

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02649790 Phase 1/2 Relapsed/Refractory Multiple Myeloma (RRMM) Completed KPTI
NCT06399640 Phase 1 Relapsed Myelodysplastic Syndrome Recruiting KPTI

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaRefractory Myelodysplastic SyndromeRelapsed Myelodysplastic SyndromeAcute Myeloid Leukemia (AML)Higher-Risk Myelodysplastic Syndrome (HR-MDS)Metastatic Castration-Resistant Prostate Cancer (mCRPC)Metastatic Colorectal Cancer (mCRC)Newly Diagnosed Intermediate/High-Risk MDSRelapsed/Refractory Multiple Myeloma (RRMM)

Other drugs acting on XPO1

More from Karyopharm Therapeutics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KPTI page.

Follow KPTI, the company behind Eltanexor

See KPTI's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KPTI catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.